MICROALLIANCE GROUP INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MICROALLIANCE GROUP INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $37.39M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $1.19M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.11M | Apr 15, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $26.97M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $1.02M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.83M | Apr 15, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $18.68M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($627.9K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($305.1K) | Apr 15, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $24.86M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($609.9K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($332.2K) | Apr 15, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $44.4K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $98.9K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $99.7K | Apr 15, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.29M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $37.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $211.7K | Apr 15, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $117.8K | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $2.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $110.9K | Apr 15, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $30.99M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $975.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.15M | Apr 15, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $2.75M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $2.01M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.50M | Apr 15, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $28.25M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($1.04M) | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | ($349.1K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($48.0K) | Apr 15, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $14.76M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | ($980.3K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($345.5K) | Apr 15, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.19M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $61.5K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $23.0K | Apr 15, 2021 |
| FY2020 | Dec 31, 2018 | $2.4K | Apr 15, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 15, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 0 | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Apr 15, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 609.32M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | 600.03M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 600.03M | Apr 15, 2021 |